Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* male aged 30 to 70 years of age~* LDL-C \<6 mmol/L~* HDL-C ≤1.2 mmol/L~* at least 2 of the following:~* insulin resistance (fasting glucose \>6 mmol/L or insulin \>10 mU/L or HOMA score \>2.5)~* central obesity (waist circumference \>=94 cm).~* plasma triglycerides \>=1.7 and \<4.5 mmol/L.~* blood pressure \>=130/ \>=85 mm Hg or on drug treatment for hypertension~Exclusion Criteria:~* LDL cholesterol \>=6 mmol/L~* pre-existing or history of cardiovascular disease, diabetes, renal dysfunction, anaemia, history of significant dyspepsia or gastrointestinal disease~* apolipoprotein genotype E2/E2

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).